In this issue:
Cabozantinib in patients with platinumrefractory metastatic urothelial carcinoma
LuPIN assesses augmentation of idronoxi therapy with targeted nuclear radiation therapy (LuPSMA-617)
LuPSMA radionuclide treatment in men with metastatic CRCP with diffuse bone marrow involvement
Oral relugolix may be a viable ADT option for men with localised prostate cancer undergoing EBRT
Gut bacteria composition drives primary resistance to cancer immunotherapy in RCC
Neoadjuvant chemohormonal therapy prior to radical prostatectomy not indicated for localised prostate cancer
ADT for prostate cancer and risk of infection by SARS-CoV-2
Multiparametric magnetic resonance imaging sequences assist in the decision making of MIBC
18F-PSMA-1007 PET-CT is diagnostically superiority for metastatic disease detection in prostate cancer
VESPER shows increased efficacy and toxicity with perioperative dd-MVAC versus GC for MIBC
Please login below to download this issue (PDF)